Original contributionRNA chromogenic in situ hybridization assay with clinical automated platform is a sensitive method in detecting high-risk human papillomavirus in squamous cell carcinoma☆
Introduction
Although more than 100 subtypes of human papillomavirus (HPV) have been reported, there are approximately 40 subtypes of HPV that can cause genital lesions, and about 15 subtypes are considered to be high risk (HR) with oncogenic potential [1]. Low-risk HPV, including most commonly types 6 and 11, are present in condyloma acuminata, which do not progress to carcinoma [2]. On the contrary, high-risk HPV, most commonly types 16 and 18, has been reported to be the etiologic agent for approximately 5% of all cancers worldwide [1]. Cervical cancers are invariably caused by high-risk HPV, with types 16 and 18 detected in 70% of cases [1]. HPV16 accounts for 85% of anal cancers and 50% of oropharyngeal cancer [1]. HPV16 and HPV18 account for 40% of vaginal, vulval, and penile cancers [1]. HPV-related carcinoma of the oropharynx, characterized histologically as predominantly nonkeratinizing with basaloid morphology, is associated with enhanced chemoradiation responsiveness and better overall survival and disease-specific survival in comparison to patients with HPV-negative carcinomas [3]. Therefore, HPV testing has clinical importance, not only prognostically but also in treatment planning.
Current methods available for HPV detection include serum antibody against several HPV epitopes, type-specific and broad-spectrum HPV epitopes, real-time polymerase chain reaction (PCR) to quantify viral load, DNA in situ hybridization (ISH), RNA ISH, and immunohistochemical stain. PCR-based detection of HPV E6 oncogene expression in frozen tissue is generally regarded as the criterion standard, although rarely performed or available clinically; HPV PCR assays are sensitive methods approved by the Food and Drug Administration for the detection and typing of HPV on formalin-fixed, paraffin-embedded tissues, but visualization of viral transcripts within the tissues is not possible by this method, unlike p16 immunostain or ISH assays using either DNA or RNA probes [4]. In addition, PCR assays cannot distinguish passenger virus from clinically relevant infection. ISH methods are more specific by providing evidence of viral DNA integration into the tumor cells (active transcription).
In daily practice, p16 immunostain has been commonly used as a surrogate marker for high-risk HPV infection in the anogenital tract. Although less expensive and highly sensitive, p16 immunostain is not a specific marker for active HPV infection, and not infrequently, p16 expression has not correlated with HPV RNA ISH results [5]. In addition, there is a subset of cervical high-grade intraepithelial lesions that has been reported to be p16 negative [6].
Currently, ISH probes are commercially available for formalin-fixed, paraffin-embedded tissue. Although prior studies have shown HPV RNA ISH methods superior to HPV DNA ISH methods [7], [8], [9], these studies used either manual or automated research protocols. Using a clinical automated platform, we aim to evaluate the performance of 2 commercially available probes on formalin-fixed, paraffin-embedded tissues—Leica DNA ISH HPV probe (Leica Microsystems, Bannockburn, IL) and Advanced Cell Diagnostics RNA ISH HPV probe (Advanced Cell Diagnostics, Newark, CA) targeting HPV E6 and E7 messenger RNA (mRNA) transcript.
Section snippets
Materials and methods
The study has been approved by Massachusetts General Hospital institutional board review (2016-P-2827). Fifty-seven cases submitted for clinical testing were identified from 2015 to 2016 in the Massachusetts General Hospital pathology files. The medical records were reviewed, and age, sex, lesion site, and tumor type were recorded.
Results
Fifty-seven samples from 57 patients were analyzed. Their age ranges from 20 to 91 years (median, 61 years). The male-to-female ratio was approximately 1:2. All were squamous cell carcinoma (SCC), with 49 cases (86%) arising from the head and neck region including tonsil, base of tongue, palate, pharynx, and larynx. Four cases (7%) were from the genital region, 3 cases (5%) from the urinary tract, and 1 case (2%) from skin of the thumb. Of the 26 cases positive by PCR, 25 cases were positive for
Discussion
HPV detection in head and neck SCC is clinically important because it has been shown to correlate with favorable clinical outcome and better response to treatment [10], [11]. In addition, HPV-related oropharyngeal carcinomas are often treated with de-escalation therapy, requiring less toxic, less invasive procedures [12]. Our study evaluated the HPV ISH methods using a clinical platform rather than a manual protocol or automated research platform used in former studies [7], [8], [9]. This is
References (22)
- et al.
In situ hybridization analysis of human papillomavirus DNA segregation patterns in lesions of the female genital tract
Gynecol Oncol
(1990) - et al.
Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing
Oral Oncol
(2010) - et al.
Treatment de-intensification strategies for head and neck cancer
Eur J Cancer
(2016) - et al.
RNAscope: a novel in situ RNA analysis platform for formalin-fixed paraffin-embedded tissues
J Mol Diagn
(2012) Practical issues in the application of p16 immunohistochemistry in diagnostic pathology
Hum Pathol
(2016)- et al.
HPV-associated head and neck cancer: a virus-related cancer epidemic
Lancet Oncol
(2010) The global health burden of infection-associated cancers in the year 2002
Int J Cancer
(2006)- et al.
p16 positive oropharyngeal squamous cell carcinoma: an entity with a favorable prognosis regardless of tumor HPV status
Am J Surg Pathol
(2010) Five FDA-approved HPV assays
MLO Med Lab Obs
(2012)- et al.
Frequency and prognostic significance of p16(INK4A) protein overexpression and transcriptionally active human papillomavirus infection in laryngeal squamous cell carcinoma
Br J Cancer
(2015)
Different patterns of p16 immunoreactivity in cervical biopsies: correlation to lesion grade and HPV detection, with a review of the literature
Eur J Gynaecol Oncol
Cited by (0)
- ☆
Disclosures: There was no external funding for this work. The authors have no conflicts of interest to declare.